A lucrative collaboration agreement with AstraZeneca sent Cellectis shares skyrocketing over 180% in premarket trading Wednesday. The pharma giant is investing $245 million in the French biotech, strengthening its commitment to developing cell and gene therapy products.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,